Descripciones mejoradas de Syndetics:

Drugs in Sport, 4th edition is a fully revised and updated version of the most comprehensive and authoritative text available on the subject. Leading figures in the field explore the hard science behind every major class of drug, as well as the social, ethical and organizational dimensions to the issue. Accessibly discussing key topics like, analysis of anabolic steroids, EPO and human growth hormone, alcohol and social drug use in sport, and creatine and nutritional supplements, this is an important text for all sports science and sports studies students, coaches and professional sports people, and sports administrators and policy-makers.

Tabla de contenidos provista por Syndetics

• Contributors(p. xi)
• 1 An introduction to drugs and their use in sport(p. 1)
• 1.1 Definition of a drug(p. 1)
• 1.2 Classification and description of drug names(p. 1)
• 1.3 Development of new drugs(p. 3)
• 1.4 Dosage forms for drug delivery to the body(p. 4)
• 1.5 The absorption, distribution, metabolism and elimination of drugs(p. 5)
• 1.6 Effect of exercise on pharmacokinetics(p. 9)
• 1.7 Drugs and their targets(p. 9)
• 1.8 Agonists and antagonists(p. 10)
• 1.9 Side-effects of drugs(p. 11)
• 1.10 Complex drug reactions(p. 13)
• 1.11 Drugs and the law(p. 14)
• 1.12 Nutritional supplements(p. 17)
• 1.13 Why drugs are used in sport(p. 20)
• 1.14 References(p. 26)
• 2 Drug use and abuse in sport(p. 29)
• 2.1 Historical perspective(p. 29)
• 2.2 Definition of doping(p. 32)
• 2.3 A review of the WADA list of doping classes and methods(p. 34)
• 2.4 The rationale for drug misuse in sport(p. 40)
• 2.5 Attitudes towards drugs in sport(p. 51)
• 2.6 Ethical issues associated with drug use in sport(p. 53)
• 2.7 An international policy perspective/government action and policy(p. 56)
• 2.8 References(p. 62)
• 3 Central nervous system stimulants(p. 64)
• 3.1 Introduction(p. 64)
• 3.2 Amphetamines(p. 64)
• 3.3 Other sympathomimetics - ephedrine, pseudoephedrine and phenylpropanolamine(p. 73)
• 3.4 Cocaine(p. 76)
• 3.5 Caffeine, theophylline and other methyl xanthines(p. 83)
• 3.6 Conclusions and the future(p. 96)
• 3.7 References(p. 96)
• 4 WADA regulations in relation to drugs used in the treatment of respiratory tract disorders(p. 103)
• 4.1 Introduction(p. 103)
• 4.2 Asthma and its treatment(p. 104)
• 4.3 Management of asthma(p. 105)
• 4.4 Pharmacology of anti-asthma drugs(p. 108)
• 4.5 Exercise and asthma(p. 114)
• 4.6 Treatment of exercise-induced asthma (EIA)(p. 116)
• 4.7 Treatment of coughs and colds(p. 120)
• 4.8 Recommendations for treatment of coughs and colds(p. 134)
• 4.9 Summary(p. 135)
• 4.10 References(p. 135)
• 5 Androgenic anabolic steroids(p. 140)
• 5.1 Summary(p. 140)
• 5.2 Introduction(p. 140)
• 5.3 The testosterone family(p. 141)
• 5.4 Structural analogues of testosterone - the anabolic steroids(p. 147)
• 5.5 Anabolic steroids and sport(p. 150)
• 5.6 Something special(p. 165)
• 5.7 Precursors, nandrolone and metabolites(p. 166)
• 5.8 Anabolic steroid side-effects with particular reference to athletes(p. 170)
• 5.9 Educational and social aspects(p. 182)
• 5.10 The future(p. 184)
• 5.11 References(p. 185)
• 6 Peptide and glycoprotein hormones and sport(p. 191)
• 6.1 Human growth hormone (hGH)(p. 191)
• 6.2 The abuse of hGH in sport(p. 196)
• 6.3 Adrenocorticotrophic hormone (ACTH)(p. 200)
• 6.4 Insulin and its use in sport(p. 201)
• 6.5 Human chorionic gonadotrophin (hCG)(p. 202)
• 6.6 Luteinizing hormone (LH) and its use in sport(p. 203)
• 6.7 References(p. 204)
• 7 Blood boosting and sport(p. 207)
• 7.1 Introduction(p. 207)
• 7.2 Erythropoiesis(p. 208)
• 7.3 Exercise at altitude(p. 212)
• 7.4 Adaptations to altitude(p. 212)
• 7.5 Blood doping(p. 216)
• 7.6 The use of erythropoietin in blood boosting(p. 217)
• 7.7 Blood substitutes(p. 220)
• 7.8 Actovegin(p. 222)
• 7.9 Testing for blood doping(p. 223)
• 7.10 Conclusions(p. 224)
• 7.11 References(p. 225)
• 8 Drug treatment of inflammation in sports injuries(p. 228)
• 8.1 Introduction(p. 228)
• 8.2 The inflammatory response(p. 229)
• 8.3 Acute and chronic inflammation(p. 237)
• 8.4 The treatment of sporting injuries(p. 239)
• 8.5 Summary(p. 256)
• 8.6 References(p. 256)
• 9 Alcohol, anti-anxiety drugs and sport(p. 258)
• 9.1 Introduction(p. 258)
• 9.2 Anxiety and performance(p. 259)
• 9.3 Alcohol(p. 261)
• 9.4 Benzodiazepines(p. 273)
• 9.5 Melatonin(p. 277)
• 9.6 Marijuana(p. 278)
• 9.7 Nicotine(p. 279)
• 9.8 Beta blockers(p. 281)
• 9.9 Overview(p. 284)
• 9.10 References(p. 285)
• 10 Creatine(p. 288)
• 10.1 Introduction(p. 288)
• 10.2 Metabolism and storage of creatine(p. 288)
• 10.3 Energy metabolism(p. 291)
• 10.4 Muscle creatine loading(p. 294)
• 10.5 Creatine and performance(p. 296)
• 10.6 Health-related aspects(p. 300)
• 10.7 Creatine and clinical use(p. 302)
• 10.8 Should creatine be banned for use in sport?(p. 303)
• 10.9 Conclusion(p. 303)
• 10.10 References(p. 303)
• 11 Doping control in sport(p. 309)
• 11.1 History of drug testing(p. 309)
• 11.2 WADA accredited laboratories(p. 316)
• 11.3 The testing programmes(p. 320)
• 11.4 Reporting test results(p. 330)
• 11.5 Problems in doping control testing(p. 333)
• 11.6 Alternatives to urine testing in doping control(p. 347)
• 11.7 Is the WADA list of banned substances and methods appropriate?(p. 349)
• 11.8 Conclusions(p. 350)
• 11.9 References(p. 351)
• 12 Prevalence of drug misuse in sport(p. 357)
• 12.1 Introduction(p. 357)
• 12.2 Statistics on doping control in sport(p. 357)
• 12.3 Surveys into drug misuse in sport(p. 370)
• 12.4 A perspective on the prevalence of drug misuse in sport through medical practitioners(p. 375)